17.07.2018
![]()
DGAP-News: STADA Arzneimittel AG: Voting results of the bondholders' meeting on July 17, 2018 concerning the STADA-Bond 2015/2022: Appointment of One Square Advisory Services GmbH as joint representative and adjournment of the further agenda items
DGAP-News: STADA Arzneimittel AG / Key word(s): Bond/Miscellaneous
STADA Arzneimittel AG: Voting results of the bondholders' meeting on July
17, 2018 concerning the STADA-Bond 2015/2022: Appointment of One Square
Advisory Services GmbH as joint representative and adjournment of the
further agenda items
17.07.2018 / 12:05
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Bad Vilbel, July 17, 2018 - STADA Arzneimittel Aktiengesellschaft ("STADA"
or the "Issuer") hereby announces the voting results of the meeting on July
17, 2018 (the "Bondholders' Meeting") of the bondholders (the "Bondholders
") of the EUR 300,000,000 1.750% Bonds, due 2022, ISIN XS1213831362, Common
Code 121383136, WKN A14KJP (the "Bonds").
The Bondholders decided to appoint One Square Advisory Services GmbH as
joint representative according to the resolution proposal of the chairman of
the meeting and the Issuer under agenda item III as amended at the
Bondholders' Meeting.
Since the Bondholders' Meeting did not reach the quorum required for the
resolutions on the authorization of the joint representative to accede to
the Intercreditor Agreement and on certain technical changes to the bond
terms and conditions, the agenda items IV and V have been adjourned to
September 18, 2018 as proposed by the chairman of the meeting and the
Issuer. The time until then is supposed to be used to mobilize a sufficient
number of Bondholders to participate.
No further resolutions were passed.
Further details of the Bondholders' Meeting, including the voting results
for each agenda item, are available on the STADA website at
www.stada.com/investor-relations/bonds.html.
About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad
Vilbel, Germany. The company focuses on a three-pillar strategy consisting
of generics, non-prescription OTC products and specialty pharmaceuticals,
biosimilars in particular. Worldwide, STADA is represented in about 30
countries with roughly 50 subsidiaries. Branded products such as Grippostad
and Ladival are among the highest selling in their product categories in
Germany. In financial year 2017, STADA achieved adjusted Group sales of Euro
2,255.3 million, adjusted earnings before interest, taxes, depreciation and
amortization (EBITDA) of Euro 433.9 million and adjusted net income of Euro
195.6 million. As of December 31, 2017, STADA employed 10,176 people
worldwide.
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad
Vilbel - Germany /
Phone: +49 (0) 6101 603-165 [IMAGE] / Fax: +49 (0) 6101 603-215 [IMAGE] /
E-Mail: [email protected]
Or visit us on the Internet at www.stada.com
Additional information for capital market participants:
STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 /
61118 Bad Vilbel - Germany /
Phone: +49 (0) 6101 603-113 [IMAGE] / Fax: +49 (0) 6101 603-215 [IMAGE] /
E-mail: [email protected]
Or visit us on the Internet at www.stada.com
---------------------------------------------------------------------------
17.07.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: [email protected]
Internet: www.stada.de
ISIN: DE0007251803
WKN: 725180
Listed: Regulated Market in Dusseldorf, Frankfurt (General
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Hanover, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
705249 17.07.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
STADA Arzneimittel AG ISIN: DE0007251803 können Sie bei EQS abrufen
Gesundheit , 725180 , SAZ , XETR:SAZ